| Gary Neil Stokes, MD | |
|
655 East 1300 North, Logan, UT 84341 | |
| (435) 792-6500 | |
| (435) 792-6608 |
| Full Name | Gary Neil Stokes |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 655 East 1300 North, Logan, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578553210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 10119882-1205 (Utah) | Primary |
| 207R00000X | Internal Medicine | 0119882-8905 (Utah) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Gary Neil Stokes, MD 655 East 1300 North, Logan, UT 84341 Ph: (435) 792-6500 | Gary Neil Stokes, MD 655 East 1300 North, Logan, UT 84341 Ph: (435) 792-6500 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.
The brain contains more cholesterol than any other organ in the body, has to produce its own cholesterol and won't function normally if it doesn't churn out enough. Defects in cholesterol metabolism have been linked with Alzheimer's disease and other neurodegenerative conditions. Now researchers at Joslin Diabetes Center have discovered that diabetes can affect how much cholesterol the brain can make.
Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.
The medical workforce of the future will not be prepared for the challenges of tomorrow's disease burden unless drastic changes are made to introduce flexible work patterns and multidisciplinary teamwork, according to a health policy expert.
› Verified 2 days ago